Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5571_Библиотеки_им_академика_М_И_Перельмана
.pdf
48. Xu, J. and Stevenson, J. Drug-like index: a new approach to measure drug-like compounds
and their diversity. J. Chem. Inf. Comput. Sci. 2000, 40, 1177–1187.
49. Jorgensen, W. L. The many roles of computation ion drug discovery. Science 2004, 303,
1813–1818.
50. Fostel, J. Predictive ADME-Tox London, UK, 27–28 April 2005. Expert Opin. Drug
Metab. Toxicol. 2005. 1, 565–570.
51. Pavan, M. and Worth, A. P. Publicly-accessible QSAR software tools developed by the
Joint Research Centre. SAR QSAR Environ. Res. 2008, 19, 785–799.
52. Summerfield, S. and Jeffrey, P. Discovery DMPK: changing paradigms in the eighties,
nineties and noughties. Expert Opin. Drug Discov. 2009, 4, 207–218.
53. Merlot, C. In silico methods for early toxicity assessment. Curr. Opin. Drug Discov.
Devel. 2008, 11, 80–85.
54. Kramer, J. A., Sagartz, J. E. and Morris, D. L. The application of discovery toxicology and
pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug
Discov. 2007, 6, 636–649.
55. Tarbit, M. H. and Berman, J. High-throughput approaches for evaluating absorption,
distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem.
Biol. 1998, 2, 411–416.
56. Di, L. and Kerns, E. H. Profiling drug-like properties in discovery research. Curr. Opin.
Chem. Biol. 2003, 7, 402–408.
57. H€am€al€ainen, M. D. and Frostell-Karlsson, A. Predicting the intestinal absorption
potential of hits and leads. Drug Discov. Today 2004, 1, 397–405.
58. Selick, H. E., Beresford, A. P., and Tarbit, M. H. The emerging importance of predictive
ADME simulation in drug discovery. Drug Discov. Today 2002, 7, 109–116.
59. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings. Adv. Drug Deliv. Rev. 1997, 46, 3–26.
60. Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., and Leeson, P. D. A comparison
of physiochemical property profiles of development and marketed oral drugs. J. Med.
Chem. 2003, 46, 1250–1256.
61. Teague, S. J., Davis, A. M., Leeson, P. D., and Oprea, T. The design of leadlike
combinatorial libraries. Angew Chem. Int. Ed. Engl. 1999, 38, 3743–3748.
62. Congreve, M., Carr, R., Murray,C., and Jhoti, H. A rule of three for fragment-based lead
discovery? Drug Discov. Today 2003, 8, 876–877.
63. Kubinyi, H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2003,
2, 665–668.
64. Oprea, T. I. and Matter, H. Integrating virtual screening in lead discovery. Curr. Opin.
Chem. Biol. 2004, 8, 349–358.
65. Rester, U. From virtuality to reality—Virtual screening in lead discovery and lead
optimization: a medicinal chemistry perspective. Curr. Opin. Drug Discov. Devel.
2008, 11, 559–568.
66. Blake, J. F.Chemoinformatics—predicting the physicochemical properties of ‘drug-like’
molecules. Curr. Opin. Biotechnol. 2000, 11, 104–107.
67. Oprea, T. I., Tropsha, A., Faulon, J. L., and Rintoul, M. D. Systems chemical biology.
Nat. Chem. Biol. 2007, 3, 447–450.
108
IN SILICO ADME/Tox PREDICTIONS
https://t.me/medicina_free
68. Van Drie, J. H. Computer-aided drug design: the next 20 years. J. Comput. Aided Mol.
Des. 2007, 21, 591–601.
69. Bajorath, J., Peltason, L., Wawer, M., Guha, R., Lajiness, M. S., and Van Drie, J. H.
Navigatingstructure–activitylandscapes. Drug Discov.Today 2009, 14(13–14), 698–705.
70. Betz, U. A. How many genomics targets can a portfolio afford? Drug Discov. Today
2005, 10, 1057–1063.
71. Betz, U. A., Farquhar, R., and Ziegelbauer, K. Genomics: success or failure to deliver drug
targets? Curr. Opin. Chem. Biol. 2005, 9, 387–391.
72. Sakiyama, Y. The use of machine learning and nonlinear statistical tools for ADME
prediction. Expert Opin. Drug Metab. Toxicol. 2009, 5, 149–169.
73. Tetko,I. V., Bruneau, P., Mewes, H. W.,Rohrer, D. C., and Poda, G. I. Can we estimate the
accuracy of ADME-Tox predictions? Drug Discov. Today 2006, 11, 700–707.
74. Gedeck, P. and Lewis, R. A. Exploiting QSAR models in lead optimization. Curr. Opin.
Drug Discov. Devel. 2008, 11, 569–575.
75. Butina, D., Segall, M. D., and Frankcombe, K. Predicting ADME properties in silico:
methods and models. Drug Discov. Today 2002, 7, S83–S88.
76. Kirchmair, J., Distinto, S., Schuster, D., Spitzer, G., Langer, T., and Wolber,G. Enhancing
drug discovery through in silico screening: strategies to increase true positives retrieval
rates. Curr. Med. Chem. 2008, 15, 2040–2053.
77. Jacob, A., Pratuangdejkul, J., Buffet, S., Launay, J. M., and Manivet, P. In silico platform
for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II:
The body in a Hilbertian space. Drug Discov. Today 2009, 14, 406–412.
78. Lajiness, M. S., Maggiora, G. M., and Shanmugasundaram, V. Assessment of the
consistency of medicinal chemists in reviewing sets of compounds. J. Med. Chem.
2004, 47, 4891–4896.
79. Testa, B., Vistoli, G., and Pedretti, A. Musings on ADME predictions and structure–activity relations. Chem. Biodivers. 2005, 2, 1411–1427.
80. Lin, J. H. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal
antibodies. Curr. Drug Metab. 2009, 10(9), 661–691.
81. Yamashita, F. and Hashida, M. In silico approaches for predicting ADME properties of
drugs. Drug Metab. Pharmacokinet. 2004, 19, 327–338.
82. Gedeck, P., Rohde, B., and Bartels, C. QSAR—how good is it in practice? Comparison of
descriptor sets on an unbiased cross section of corporate data sets. J. Chem. Inf. Model
2006, 46, 1924–1936.
83. Villar, H. O., Hansen, M. R., and Kho, R. Substructural analysis in drug discovery. Curr.
Comput. Aided Drug Des.
2007, 3, 59–67.
84. Huang, W., Lee, S. L., and Yu, L. X. Mechanistic approaches to predicting oral drug
absorption. AAPS J. 2009, 11(2), 225–237.
85. Helguera, A. M., Combes, R. D., Gonzalez, M. P., and Cordeiro, M. N. Applications of
2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem. 2008, 8,
1628–1655.
86. Tetko, I. V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin,
V. A., Radchenko, E. V., Zefirov, N. S., Makarenko, A. S., Tanchuk, V. Y., and
Prokopenko, V. V. Virtual computational chemistry laboratory—design and description.
J. Comput. Aided Mol. Des. 2005, 19, 453–463.
REFERENCES 109
https://t.me/medicina_free
87. Zheng, S., Luo, X., Chen, G., Zhu, W., Shen, J., Chen, K., and Jiang, H. A new rapid and
effective chemistry space filter in recognizing a druglike database. J. Chem. Inf. Model
2005, 45, 856–862.
88. Hastie, T., Tibshirani, R., and Friedman, J. The Elements of Statistical Learning: Data
Mining, Inference, and Prediction, 2nd Edition, Springer Series in Statistics. Springer,
Berlin, 2009.
89. Hartigan, J. A. Clustering Algorithms, Wiley New York, 1975.
90. Jolliffe, I. T. Principal Component Analysis, ed. Statistics, S. S. i., 2002.
91. Hopfield, J. J. Neural networks and physical systems with emergent collective computational abilities. Proc. Natl. Acad. Sci. USA 1982, 79, 2554–2558.
92. Anderson, T. W. An Introduction to Multivariate Statistics. Wiley Series in Probability
and Statistics, Wiley, New York, 2003, p. 752.
93. Cover, T. M. and Hart, P. Nearest neighbor pattern classification. Proc. IEEE—Trans.
Inform. Theory 1967, IT-11, 21–27.
94. Draper, N. R. and Smith, H. Applied Regression Analysis, Wiley New York, 1966,
p. 407.
95. Wold, S. PLS in Chemistry. In The Encyclopedia in Chemistry, Wiley New York, 1999.
96. Wold, S. Nonlinear partial least squares modelling II. Chem. Intell. Lab. Syst. 1992, 14,
71–84.
97. Quinlan, J. Induction of decision trees. Mach. Learn., 1986, 1, 81–106.
98. Vapnik, V. The Nature of Statistical Learning Theory, 2nd Edition, Wiley-Interscience,
New York, 2000.
99. Stone, M. Cross-validatory choice and assessment of statistical predictions. J. Roy.
Statist. Soc. 1974, 36, 111–147.
100. Efron, B. Estimating the error rate of a prediction rule: improvement on cross-validation.
JASA 1983, 78, 316–331.
101. Balakin, K. V., Ivanenkov, Y. A., Savchuk, N. P., Ivashchenko, A. A., and Ekins,
S. Comprehensive computational assessment of ADME properties using mapping
techniques. Curr. Drug Discov. Technol. 2005, 2, 99–113.
102. Barbosa, F.and Horvath, D. Molecular similarity and property similarity. Curr. Top. Med.
Chem. 2004, 4, 589–600.
103. Baskin, I. and Varnek, A. Building a chemical space based on fragment descriptors.
Comb. Chem. High Throughput Screen 2008, 11, 661–668.
104. Willett, P. Chemoinformatics—similarity and diversity in chemical libraries. Curr. Opin.
Biotechnol. 2000, 11, 85–88.
105. Jonsdottir, S. O., Jorgensen, F. S., and Brunak, S. Prediction methods and databases within
chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics 2005, 21,
2145–2160.
106. Lombardo, F., Gifford, E., and Shalaeva, M. Y. In silico ADME prediction: data, models,
facts and myths.
Mini. Rev. Med. Chem. 2003, 3, 861–875.
107. Sakaeda, T., Okamura, N., Nagata, S., Yagami, T., Horinouchi, M., Okumura, K.,
Yamashita, F., and Hashida, M. Molecular and pharmacokinetic properties of 222
commercially available oral drugs in humans. Biol. Pharm. Bull. 2001, 24, 935–940.
108. Walters,W.P. and Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev.
Drug Discov. 2003, 2, 259–266.
110
IN SILICO ADME/Tox PREDICTIONS
https://t.me/medicina_free
109. Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. A knowledge-based approach
in designing combinatorial or medicinal chemistry libraries for drug discovery. 1.
A qualitative and quantitative characterization of known drug databases. J. Comb. Chem.
1999, 1, 55–68.
110. Charifson, P. S. and Walters, W. P.Filtering databases and chemical libraries. Mol. Divers.
2002, 5, 185–197.
111. Ajay, A., Walters, W. P., and Murcko, M. A. Can we learn to distinguish between
“drug-like” and “nondrug-like” molecules? J. Med. Chem. 1998, 41, 3314–3324.
112. Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., and Kopple, K. D.
Molecular properties that influence the oral bioavailability of drug candidates. J. Med.
Chem. 2002, 45, 2615–2623.
113. Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A.,
Durst, G. L., and Hipskind, P. A. Characteristic physical properties and structural
fragments of marketed oral drugs. J. Med. Chem. 2004, 47, 224–232.
114. Ritchie, T. J., Luscombe, C. N., and Macdonald, S. J. Analysis of the calculated
physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?
J. Chem. Inf. Model 2009, 49, 1025–1032.
115. O’Shea, R. and Moser, H. E. Physicochemical properties of antibacterial compounds:
implications for drug discovery. J. Med. Chem. 2008, 51, 2871–2878.
116. Ritchie, T. J. and Macdonald, S. J. The impact of aromatic ring count on compound
developability—are too many aromatic rings a liability in drug design? Drug Discov.
Today 2009, 14(21–22), 1011–1020.
117. Lagorce, D., Sperandio, O., Galons, H., Miteva, M. A., and Villoutreix, B. O. FAFDrugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology
projects. BMC Bioinformatics 2008, 9, 396.
118. Monge, A., Arrault, A., Marot, C., and Morin-Allory, L. Managing, profiling and
analyzing a library of 2.6 million compounds gathered from 32 chemical providers.
Mol. Divers. 2006, 10, 389–403.
119. Dubois, J., Bourg, S., Vrain, C., and Morin-Allory, L. Collections of compounds—how to
deal with them? Current Comput. Aided Drug Des. 2008, 4, 156–168.
120. Muegge, I., Heald, S. L., and Brittelli, D. Simple selection criteria for drug-like chemical
matter. J. Med. Chem. 2001, 44, 1841–1846.
121. Muegge, I. Synergies of virtual screening approaches. Mini. Rev. Med. Chem. 2008, 8,
927–933.
122. Manly, C. J., Chandrasekhar, J., Ochterski, J. W., Hammer, J. D., and Warfield, B. B.
Strategies and tactics for optimizing the hit-to-lead process and beyond—a computational
chemistry perspective. Drug Discov. Today 2008, 13, 99–109.
123. Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., and
Hinzen, B. Improving the hit-to-lead process: data-driven assessment of drug-like and
lead-like screening hits. Drug Discov. Today 2006, 11, 175–180.
124. Leeson, P. D. and Springthorpe, B. The influence of drug-like concepts on decisionmaking in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881–890.
125. G
ill, A. L., Verdonk, M., Boyle, R. G., and Taylor, R. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer
protein kinase inhibitors in clinical development. Curr. Top. Med. Chem. 2007, 7,
1408–1422.
REFERENCES 111
https://t.me/medicina_free
126. Bhal, S. K., Kassam, K., Peirson, I. G., and Pearl, G. M. The Rule of Five revisited:
applying log D in place of log P in drug-likeness filters. Mol. Pharm. 2007, 4, 556–560.
127. Mannhold, R., Poda, G. I., Ostermann, C., and Tetko, I. V. Calculation of molecular
lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000
compounds. J. Pharm. Sci. 2009, 98, 861–893.
128. Kah, M. and Brown, C. D. Log D: lipophilicity for ionisable compounds. Chemosphere
2008, 72, 1401–1408.
129. Mitra, R., Shyam, R., Mitra, I., Miteva, M. A., and Alexov, E. Calculating the protonation
states of proteins and small molecules: implications to ligand–receptor interactions.
Curr. Comput. Aided Drug Des. 2008, 4, 169–179.
130. Meloun, M. and Bordovska, S. Benchmarking and validating algorithms that estimate
pK
a
values of drugs based on their molecular structures. Anal. Bioanal. Chem. 2007, 389,
1267–1281.
131. Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., and Uchimaya,
M. Epik: a software program for pK
a
prediction and protonation state generation for
drug-like molecules. J. Comput. Aided Mol. Des. 2007, 21, 681–691.
132. Lee, A. C., Yu,J. Y., and Crippen, G. M. pK
a
prediction of monoprotic small molecules the
SMARTS way. J. Chem. Inf. Model 2008, 48, 2042–2053.
133. Ten Brink, T. and Exner, T. E. Influence of protonation, tautomeric, and stereoisomeric states on protein–ligand docking results. J. Chem. Inf. Model 2009, 49(6),
1535–1546.
134. Bayden, A. S., Fornabaio, M., Scarsdale, J. N., and Kellogg, G. E. Web application for
studying the free energy of binding and protonation states of protein–ligand complexes
based on HINT. _J. Comput. Aided Mol. Des. 2009, 23, 621–632.
135. Burton, P. S., Goodwin, J. T., Vidmar, T. J., and Amore, B. M. Predicting drug absorption:
how nature made it a difficult problem. J. Pharmacol. Exp. Ther. 2002, 303, 889–895.
136. Clark, D. E. and Pickett, S. D. Computational methods for the prediction of druglikeness. Drug Discov. Today 2000, 5, 49–58.
137. Johnson, S. R. and Zheng, W. Recent progress in the computational prediction of aqueous
solubility and absorption. AAPS J. 2006, 8, E27–E40.
138. Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P., and Pelkonen, O. In silico
prediction of ADME and pharmacokinetics. Report of an expert meeting organised by
COST B15. Eur. J. Pharm. Sci. 2002, 17, 183–193.
139. Kerns, E. H., Di, L., Petusky, S., Kleintop, T., Huryn, D., McConnell, O., and Carter, G.
Pharmaceutical profiling method for lipophilicity and integrity using liquid
chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life
Sci. 2003, 791, 381–388.
140. Goller, A. H., Hennemann, M., Keldenich, J., and Clark, T. In silico prediction of buffer
solubility based on quantum-mechanical and HQSAR- and topology-based descriptors.
J. Chem. Inf. Model 2006, 46, 648–658.
141. Faller, B. and Ertl, P. Computational approaches to determine drug solubility. Adv. Drug
Deliv. Rev. 2007, 59, 533–545.
142. Jorgensen, W. L. and Duffy, E. M. Prediction of drug solubility from structure. Adv. Drug
Deliv. Rev. 2002, 54, 355–366.
143. Hansen, N. T., Kouskoumvekaki, I., Jorgensen, F. S., Brunak, S., and Jonsdottir, S. O.
Prediction of pH-dependent aqueous solubility of druglike molecules. J. Chem. Inf.
Model 2006, 46, 2601–2619.
112
IN SILICO ADME/Tox PREDICTIONS
https://t.me/medicina_free
144. Egan, W. J. and Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev.
2002, 54, 273–289.
145. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb.
J. Med. Chem. 2008, 51, 817–834.
146. Di, L. and Kerns, E. H. Application of pharmaceutical profiling assays for optimization of
drug-like properties. Curr. Opin. Drug Discov. Devel. 2005, 8, 495–504.
147. Di, L. and Kerns, E. H. Solution stability—plasma, gastrointestinal, bioassay. Curr. Drug
Metab. 2008, 9, 860–868.
148. Eros, D., Keri, G., Kovesdi, I., Szantai-Kis, C., Meszaros, G., and Orfi, L. Comparison of
predictive ability of water solubility QSPR models generated by MLR, PLS and ANN
methods. Mini. Rev. Med. Chem. 2004, 4, 167–177.
149. Hou, T., Wang, J., Zhang, W., Wang, W., and Xu, X. Recent advances in computational
prediction of drug absorption and permeability in drug discovery.Curr. Med. Chem. 2006,
13, 2653–2667.
150. Lennernas, H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
Curr. Drug Metab. 2007, 8, 645–657.
151. Ekins, S., Nikolsky, Y., and Nikolskaya, T. Techniques: application of systems biology to
absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci.
2005, 26, 202–209.
152. Hurst, S., Loi, C. M., Brodfuehrer, J., and El-Kattan, A. Impact of physiological,
physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin. Drug Metab.
Toxicol. 2007, 3, 469–489.
153. Dokoumetzidis, A., Valsami, G., and Macheras, P. Modelling and simulation in drug
absorption processes. Xenobiotica 2007, 37, 1052–1065.
154. Lu, J. J., Crimin, K., Goodwin, J. T., Crivori, P., Orrenius, C., Xing, L., Tandler, P. J.,
Vidmar, T. J., Amore, B. M., Wilson, A. G., Stouten, P. F., and Burton, P. S. Influence of
molecular flexibility and polar surface area metrics on oral bioavailability in the rat.
J. Med. Chem. 2004, 47, 6104–6107.
155. Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164–3170.
156. Hou, T., Wang, J., Zhang, W., and Xu, X. ADME evaluation in drug discovery.6. Can oral
bioavailability in humans be effectively predicted by simple molecular property-based
rules? J. Chem. Inf. Model 2007, 47, 460–463.
157. Mensch, J., Oyarzabal, J., Mackie, C., and Augustijns, P. In vivo, in vitro and in silico
methods for small molecule transfer across the BBB. J. Pharm. Sci. 2009, 98(12),
4429–4468.
158. Palmer, A. M. and Stephenson, F.A. CNS drug discovery: challenges and solutions. Drug
News Perspect. 2005, 18, 51–57.
159. Ecker, G. F. and Noe, C. R. In silico prediction models for blood–brain barrier permeation.
Curr. Med. Chem.
2004, 11, 1617–28.
160. Goodwin, J. T. and Clark, D. E. In silico predictions of blood–brain barrier
penetration: considerations to “keep in mind.” J. Pharmacol. Exp. Ther. 2005, 315,
477–483.
161. Abbott, N. J., Dolman, D. E., and Patabendige, A. K. Assays to predict drug permeation
across the blood–brain barrier, and distribution to brain. Curr. Drug Metab. 2008, 9,
901–910.
REFERENCES 113
https://t.me/medicina_free
162. Podlogar, B. L. and Muegge, I. “Holistic” in silico methods to estimate the systemic and
CNS bioavailabilities of potential chemotherapeutic agents. Curr. Top. Med. Chem. 2001,
1, 257–275.
163. Hitchcock, S. A. Blood–brain barrier permeability considerations for CNS-targeted
compound library design. Curr. Opin. Chem. Biol. 2008, 12, 318–323.
164. Clark, D. E. In silico prediction of blood–brain barrier permeation. Drug Discov. Today
2003, 8, 927–933.
165. Allen, D. D. and Geldenhuys, W. J. Molecular modeling of blood–brain barrier nutrient
transporters: in silico basis for evaluation of potential drug delivery to the central nervous
system. Life Sci. 2006, 78, 1029–1033.
166. Feng, M. R. Assessment of blood–brain barrier penetration: in silico, in vitro and in vivo.
Curr. Drug Metab. 2002, 3, 647–657.
167. Lobell, M., Molnar, L., and Keseru, G. M. Recent advances in the prediction of
blood–brain partitioning from molecular structure. J. Pharm. Sci. 2003, 92, 360–370.
168. Ekins, S. and Tropsha, A. A turning point for blood–brain barrier modeling. Pharm. Res.
2009, 26, 1283–1284.
169. Eyal, S., Hsiao, P., and Unadkat, J. D. Drug interactions at the blood–brain barrier: fact or
fantasy? Pharmacol. Ther. 2009, 123, 80–104.
170. Norinder, U. and Bergstrom, C. A. Prediction of ADMET Properties. ChemMedChem.
2006, 1, 920–937.
171. Rose, K., Hall, L. H., and Kier, L. B. Modeling blood–brain barrier partitioning using
the electrotopological state. J. Chem. Inf. Comput. Sci. 2002, 42, 651–666.
172. Chang, C., Ekins, S., Bahadduri, P., and Swaan, P. W. Pharmacophore-based discovery of
ligands for drug transporters. Adv. Drug Deliv. Rev. 2006, 58, 1431–1450.
173. Gozalbes, R., Barbosa, F., Nicolai, E., Horvath, D., and Froloff, N. Development and
validation of a pharmacophore-based QSAR model for the prediction of CNS activity.
ChemMedChem 2009, 4, 204–209.
174. Chang, C., Bahadduri, P. M., Polli, J. E., Swaan, P. W., and Ekins, S. Rapid identification
of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos. 2006, 34, 1976–1984.
175. Ekins, S., Ecker, G. F., Chiba, P., and Swaan, P. W. Future directions for drug transporter
modelling. Xenobiotica 2007, 37, 1152–1170.
176. Seigneuret, M. and Garnier-Suillerot, A. A structural model for the open conformation of
the mdr1 P-glycoprotein based on the MsbA crystal structure. J. Biol. Chem. 2003, 278,
30115–30124.
177. Ravna, A. W., Sylte, I., and Dahl, S. G. Structure and localisation of drug binding sites
on neurotransmitter transporters.
J. Mol. Model. 2009, 15(10), 1155–1164.
178. Fenner, K. S., Troutman, M. D., Kempshall, S., Cook, J. A., Ware,J. A., Smith, D. A., and
Lee, C. A. Drug–drug interactions mediated through P-glycoprotein: clinical relevance
and in vitro–in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther.
2009, 85, 173–181.
179. Crivori, P., Reinach, B., Pezzetta, D., and Poggesi, I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm. 2006, 3, 33–44.
180. Cianchetta, G., Singleton, R. W., Zhang, M., Wildgoose, M., Giesing, D., Fravolini, A.,
Cruciani, G., and Vaz, R. J. A pharmacophore hypothesis for P-glycoprotein substrate
recognition using GRIND-based 3D-QSAR. J. Med. Chem. 2005, 48, 2927–2935.
114
IN SILICO ADME/Tox PREDICTIONS
https://t.me/medicina_free
181. Osterberg, T. and Norinder, U. Theoretical calculation and prediction of P-glycoproteininteracting drugs using MolSurf parametrization and PLS statistics. Eur J. Pharm. Sci.
2000, 10, 295–303.
182. Xue, Y., Yap, C. W., Sun, L. Z., Cao, Z. W., Wang, J. F., and Chen, Y. Z. Prediction of
P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comput.
Sci. 2004, 44, 1497–1505.
183. Wang, Y. H., Li, Y., Yang, S. L., and Yang, L. Classification of substrates and inhibitors of
P-glycoprotein using unsupervised machine learning approach. J. Chem. Inf. Model 2005,
45, 750–757.
184. Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M.,
Trinh, Y. T., Zhang, Q., Urbatsch, I. L., and Chang, G. Structure of P-glycoprotein
reveals a molecular basis for poly-specific drug binding. Science 2009, 323,
1718–1722.
185. Gottesman, M. M., Ambudkar, S. V., and Xia, D. Structure of a multidrug transporter.
Nat. Biotechnol. 2009, 27, 546–547.
186. Kragh-Hansen, U., Chuang, V. T., and Otagiri, M. Practical aspects of the ligand-binding
and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25,
695–704.
187. Zsila, F., Fitos, I., Bencze, G., Keri, G., and Orfi, L. Determination of human serumalpha
(1)-acid glycoprotein and albumin binding of various marketed and preclinical kinase
inhibitors. Curr. Med. Chem. 2009, 16, 1964–1977.
188. Schonfeld, D. L., Ravelli, R. B., Mueller, U., and Skerra, A. The 1.8-A crystal structure of
alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drugbinding activity of this human plasma lipocalin. J. Mol. Biol. 2008, 384, 393–405.
189. Estrada, E., Uriarte, E., Molina, E., Simon-Manso, Y., and Milne, G. W. An integrated
in silico analysis of drug-binding to human serum albumin. J. Chem. Inf. Model 2006, 46,
2709–2724.
190. Gunturi, S. B., Narayanan, R., and Khandelwal, A. In silico ADME modelling 2:
computational models to predict human serum albumin binding affinity using ant colony
systems. Bioorg. Med. Chem. 2006, 14, 4118–4129.
191. Grossman, I. ADME pharmacogenetics: current practices and future outlook. Expert
Opin. Drug Metab. Toxicol. 2009, 5, 449–462.
192. de Groot, M. J., Wakenhut, F., Whitlock, G., and Hyland, R. Understanding CYP2D6
interactions. Drug Discov. Today 2009, 14(19–20), 964–972.
193. Burton, J., Ijjaali, I., Barberan, O., Petitet, F., Vercauteren, D. P.,and Michel, A. Recursive
partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance
of the quality of the dataset. J. Med. Chem. 2006, 49, 6231–6240.
194. Liebler, D. C. and Guengerich, F. P. Elucidating mechanisms of drug-induced toxicity.
Nat. Rev. Drug Discov. 2005, 4, 410–420.
195. Raschi, E., Ceccarini, L., De Ponti, F.,and Recanatini, M. hERG-related drug toxicity and
models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab.
Toxicol. 2009, 5(9), 1005–1021.
196. Mayer, J., Cheeseman, M. A., and Twaroski, M. L. Structure-activity relationship analysis
tools: validation and applicability in predicting carcinogens. Regul. Toxicol. Pharmacol.
2008,
50, 50–58.
REFERENCES 115
https://t.me/medicina_free
197. Ashby, J. and Tennant, R. W. Prediction of rodent carcinogenicity for 44 chemicals:
results. Mutagenesis 1994, 9, 7–15.
198. Nassar, A. E., Kamel, A. M., and Clarimont, C. Improving the decision-making process in
structural modification of drug candidates: reducing toxicity. Drug Discov. Today 2004,
9, 1055–1064.
199. Shenton, J. M., Chen, J., and Uetrecht, J. P.Animal models of idiosyncratic drug reactions.
Chem. Biol. Interact. 2004, 150, 53–70.
200. Williams, D. P. and Park, B. K. Idiosyncratic toxicity: the role of toxicophores and
bioactivation. Drug Discov. Today 2003, 8, 1044–1050.
201. Greene, N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv.
Rev. 2002, 54, 417–431.
202. Gepp, M. M. and Hutter, M. C. Determination of hERG channel blockers using a decision
tree. Bioorg. Med. Chem. 2006, 14, 5325–5332.
203. Aronov, A. M. Predictive in silico modeling for hERG channel blockers. Drug Discov.
Today 2005, 10, 149–155.
204. Benz, R. D. Toxicological and clinical computational analysis and the US FDA/CDER.
Expert Opin. Drug Metab. Toxicol. 2007, 3, 109–1024.
205. Yang, C., Benz, R. D., and Cheeseman, M. A. Landscape of current toxicity databases and
database standards. Curr. Opin. Drug Discov. Devel. 2006, 9, 124–133.
206. Shelat, A. A. and Guy, R. K. The interdependence between screening methods and
screening libraries. Curr. Opin. Chem. Biol. 2007, 11, 244–251.
207. Wren, J. D. and Bateman, A. Databases, data tombs and dust in the wind. Bioinformatics
2008, 24, 2127–2128.
208. Zvinavashe, E., Murk, A. J., and Rietjens, I. M. Promises and pitfalls of quantitative
structure–activity relationship approaches for predicting metabolism and toxicity. Chem.
Res. Toxicol. 2008, 21(12), 2229–2236.
209. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discov. Today 2002, 7,
1047–1055.
210. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26.
211. Rishton, G. M. Reactive compounds and in vitro fake positives in HTS. Drug Discov.
Today 1997, 2, 382–384.
212. Seidler, J., McGovern, S. L., Doman, T. N., and Shoichet, B. K. Identification and
prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem.
2003, 46, 4477–4486.
213. McGovern, S. L., Helfand, B. T., Feng, B., and Shoichet, B. K. A specific mechanism of
nonspecific inhibition. J. Med. Chem.
2003, 46, 4265–4272.
214. Roche, O., Schneider, P., Zuegge, J., Guba, W., Kansy, M., Alanine, A., Bleicher,
K., Danel, F., Gutknecht, E. M., Rogers-Evans, M., Neidhart, W., Stalder, H., Dillon,
M., Sjogren, E., Fotouhi, N., Gillespie, P., Goodnow, R., Harris, W., Jones, P., Taniguchi,
M., Tsujii, S., von der Saal, W., Zimmermann, G., and Schneider, G. Development of a
virtual screening method for identification of “frequent hitters” in compound libraries.
J. Med. Chem. 2002, 45, 137–142.
116
IN SILICO ADME/Tox PREDICTIONS
https://t.me/medicina_free
215. Oprea, T. I. Property distribution of drug-related chemical databases. J. Comput. Aided
Mol. Des. 2000, 14, 251–264.
216. SD File format. Available at http://www.mdl.com/downloads/public/ctfile/ctfile.pdf,
2007, MDL—Symix.
217. Daylight Chemical Information Systems, Inc. SMILES—Simplified Molecular Input
Line Entry System. 2009.
218. Daylight Chemical Information Systems Inc, SMARTS—A Language for Describing
Molecular Patterns. 2007. Aliso Viejo, CA.
219. InChI The IUPAC International Chemical Identifier. 2009.
220. Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., Cathey, T., Transue,
T. R., Spencer, R., and Wolf, M. ACToR—Aggregated Computational Toxicology
Resource. Toxicol. Appl. Pharmacol. 2008, 233, 7–13.
221. AKos. Consulting & Solutions GmbH—Screening Compound Business. 2009.
222. Tong, J. C., Lim, S. J., Muh, H. C., Chew, F. T., and Tammi, M. T. Allergen Atlas: a
comprehensive knowledge center and analysis resource for allergen information. Bio-
informatics 2009, 25, 979–980.
223. He, Q. Y., He, Q. Z., Deng, X. C., Yao, L., Meng, E., Liu, Z. H., and Liang, S. P. ATDB: a
uni-database platform for animal toxins. Nucleic Acids Res. 2008, 36, D293–D297.
224. Chang, A., Scheer, M., Grote, A., Schomburg, I., and Schomburg, D. BRENDA,
AMENDA and FRENDA the enzyme information system: new content and tools in
2009. Nucleic Acids Res. 2009 37, D588–D592.
225. Ott, M. A. and Vriend, G. Correcting ligands, metabolites, and pathways. BMC
Bioinformatics 2006, 7, 517.
226. Degtyarenko, K., de Matos, P., Ennis, M., Hastings, J., Zbinden, M., McNaught, A.,
Alcantara, R., Darsow, M., Guedj, M., and Ashburner,M. ChEBI: a database and ontology
for chemical entities of biological interest. Nucleic Acids Res. 2008, 36, D344–D350.
227. Seiler, K. P., George, G. A., Happ, M. P., Bodycombe, N. E., Carrinski, H. A., Norton, S.,
Brudz, S., Sullivan, J. P., Muhlich, J., Serrano, M., Ferraiolo, P., Tolliday, N. J., Schreiber,
S. L., and Clemons, P. A. ChemBank: a small-molecule screening and cheminformatics
resource database. Nucleic Acids Res. 2008, 36, D351–D359.
228. Williams, A. J. A perspective of publicly accessible/open-access chemistry databases.
Drug Discov. Today 2008, 13, 495–501.
229. Naamati, G., Askenazi, M., and Linial, M. ClanTox: a classifier of short animal toxins.
Nucleic Acids Res. 2009, 37, W363–W368.
230. Zhang, J. X., Huang, W.J., Zeng, J. H., Huang, W. H., Wang, Y.,Zhao, R., Han, B. C., Liu,
Q. F., Chen, Y. Z., and Ji, Z. L. DITOP: drug-induced toxicity related protein database.
Bioinformatics 2007, 23, 1710–1712.
231. Richard, A. M. and Williams, C. R. Distributed structure-searchable toxicity (DSSTox)
public database network: a proposal. Mutat. Res. 2002, 499, 27–52.
232. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P.,
Chang, Z., and Woolsey, J. DrugBank: a comprehensive resource for in silico drug
discovery and exploration. Nucleic Acids Res. 2006,
34, D668–D672.
233. Huang, N., Shoichet, B. K., and Irwin, J. J. Benchmarking sets for molecular docking.
J. Med. Chem. 2006, 49, 6789–801.
234. eMolecules. Del Mar, CA, USA. Available at http://www.emolecules.com, 2008.
REFERENCES 117
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана